Results 61 to 70 of about 4,500,736 (296)

Capsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cells. [PDF]

open access: yes, 2012
Cryptococcosis is a life-threatening fungal disease with a high rate of mortality among HIV/AIDS patients across the world. The ability to penetrate the blood-brain barrier (BBB) is central to the pathogenesis of cryptococcosis, but the way in which this
May, Robin C   +10 more
core   +2 more sources

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Potential therapeutic molecular targets for blood-brain barrier disruption after subarachnoid hemorrhage

open access: yesNeural Regeneration Research, 2019
Aneurysmal subarachnoid hemorrhage remains serious hemorrhagic stroke with high morbidities and mortalities. Aneurysm rupture causes arterial bleeding-induced mechanical brain tissue injuries and elevated intracranial pressure, followed by global ...
Hideki Kanamaru, Hidenori Suzuki
doaj   +1 more source

B3Pred: A Random-Forest-Based Method for Predicting and Designing Blood–Brain Barrier Penetrating Peptides

open access: yesPharmaceutics, 2021
The blood–brain barrier is a major obstacle in treating brain-related disorders, as it does not allow the delivery of drugs into the brain. We developed a method for predicting blood–brain barrier penetrating peptides to facilitate drug delivery into the
Vinod Kumar   +4 more
doaj   +1 more source

Aquaporin and Blood Brain Barrier [PDF]

open access: yesCurrent Neuropharmacology, 2010
Large water fluxes continuously take place between the different compartments of the brain as well as between the brain parenchyma and the blood or cerebrospinal fluid.Disturbances in this well-regulated water homeostasis may have deleterious effects on brain function and may be fatal in cases where water accumulates in the brain following pathologies ...
Francesca, Bonomini   +2 more
openaire   +3 more sources

Nanoparticulate transport of oximes over an in vitro blood-brain barrier model [PDF]

open access: yes, 2010
Background: Due to the use of organophosphates (OP) as pesticides and the availability of OP-type nerve agents, an effective medical treatment for OP poisonings is still a challenging problem.
Tikva Vogel   +19 more
core   +2 more sources

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

open access: yesFEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

In vitro model of the blood-brain barrier established by co-culture of primary cerebral microvascular endothelial and astrocyte cells

open access: yesNeural Regeneration Research, 2015
Drugs for the treatment and prevention of nervous system diseases must permeate the blood-brain barrier to take effect. In vitro models of the blood-brain barrier are therefore important in the investigation of drug permeation mechanisms.
Yan Wang   +5 more
doaj   +1 more source

A breach in the blood-brain barrier [PDF]

open access: yesProceedings of the National Academy of Sciences, 2005
A fundamental problem affecting the efficacy of drugs is their ability to be delivered from the site of administration to the site of pathology. Nowhere is this issue a more confounding problem than for protein drugs designed to treat the neuropathology associated with many lysosomal storage diseases (LSDs) where the blood-brain barrier (BBB) stands in
openaire   +2 more sources

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

open access: yesFEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy